Clearbridge Health’s Strategic Rights Issue Receives Regulatory Green Light

Clearbridge Health Limited has achieved a significant milestone as it announces the receipt of the listing and quotation notice from the Singapore Exchange Securities Trading Limited (SGX-ST) for its proposed renounceable non-underwritten rights issue. This development, announced by the Board of Directors on 28 October 2024, marks a pivotal step in the company’s capital strategy.

The rights issue involves offering up to 1,279,125,560 new ordinary shares on the Catalist Board of the SGX-ST. This move was previously approved by shareholders in an extraordinary general meeting held on 23 October 2024. The listing and quotation notice, however, is contingent upon Clearbridge Health complying with SGX-ST’s listing requirements.

Despite this regulatory approval, Clearbridge Health emphasizes that the listing and quotation notice should not be perceived as an indication of the merits of the proposed rights issue or the company itself. Shareholders and potential investors are urged to exercise caution, as there is no certainty that the rights issue will be completed or that the terms will remain unchanged.

To stay informed on further developments, stakeholders are advised to monitor subsequent announcements from Clearbridge Health. Additionally, consulting with financial advisors, such as stockbrokers or accountants, is recommended for those uncertain about their course of action.

This announcement has been prepared in consultation with the company’s sponsor, ZICO Capital Pte. Ltd. However, it is important to note that the SGX-ST has not reviewed or approved the announcement’s contents and holds no responsibility for its accuracy.